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Abstract
Background: The tight organisation of eukaryotic genomes as chromatin hinders the interaction
of many DNA-binding regulators. The local accessibility of DNA is regulated by many chromatin
modifying enzymes, among them the nucleosome remodelling factors. These enzymes couple the
hydrolysis of ATP to disruption of histone-DNA interactions, which may lead to partial or
complete disassembly of nucleosomes or their sliding on DNA. The diversity of nucleosome
remodelling factors is reflected by a multitude of ATPase complexes with distinct subunit
composition.
Results: We found further diversification of remodelling factors by posttranslational modification.
The histone acetyltransferase GCN5 can acetylate the Drosophila remodelling ATPase ISWI at a
single, conserved lysine, K753, in vivo and in vitro. The target sequence is strikingly similar to the N-
terminus of histone H3, where the corresponding lysine, H3K14, can also be acetylated by GCN5.
The acetylated form of ISWI represents a minor species presumably associated with the
nucleosome remodelling factor NURF.
Conclusion: Acetylation of histone H3 and ISWI by GCN5 is explained by the sequence similarity
between the histone and ISWI around the acetylation site. The common motif RKT/SxGx(Kac)xPR/
K differs from the previously suggested GCN5/PCAF recognition motif GKxxP. This raises the
possibility of co-regulation of a nucleosome remodelling factor and its nucleosome substrate
through acetylation of related epitopes and suggests a direct crosstalk between two distinct
nucleosome modification principles.
Background
Disruption of DNA-histone interactions by nucleosome
remodelling ATPases may lead to a variety of transitions
of chromatin structure, such as the partial or complete dis-
assembly of nucleosomes, the exchange of histones, or the
sliding of intact histone octamers on DNA [1-4]. In many
cases their activity is focused on local disruption of the
nucleosomal fibre through recruitment of DNA-binding
regulators to promote access of factors further down-
stream in the cascade of events that leads to promoter
opening [2]. However, genome-wide processes like repli-
cation, DNA damage responses or homologous recombi-
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nation require chromatin to be dynamic on a global scale.
In addition to generating local access to nucleosomal
DNA, nucleosome disruption may also have profound
consequences for the folding of the nucleosomal fibre
into higher order structures [5,6].
One largely unresolved issue to date is how the activity of
chromatin remodelling enzymes is regulated. Established
regulatory principles that govern, for example, metabolic
enzymes also apply to nucleosome remodelling ATPases,
but our knowledge is still anecdotal. The expression of
nucleosome remodelling ATPases may be selective. For
example, the fact that the mammalian ISWI isoform
SNF2H is abundant in proliferating cells, whereas the
related SNF2L is enriched in terminally differentiated neu-
rons points to functional diversification of related remod-
elling enzymes and specialized roles in proliferation/
differentiation control [7]. Such a role has also been sug-
gested for the SWI2/SNF2-type ATPase hBRM by the early
finding that its expression is down-regulated when cells
receive a mitogenic stimulus or during ras-mediated onco-
genic transformation, whereas its forced expression par-
tially reverses transformation [8].
A further regulatory strategy involves post-translational
modifications of enzymes, such as their phosphorylation.
Phosphorylation of hBRM and BRG-1 during mitosis cor-
relates with dissociation of these remodellers from the
chromosomes during condensation [9]. Muchardt and
colleagues also showed that acetylation of hBRM corre-
lates with a reduced inhibition of cell growth [10]. The
possibility of regulating nucleosome remodelling ATPases
by lysine acetylation is intriguing given that properties of
their substrates, the histones, are most prominently mod-
ulated by acetylation at their exposed N-termini [11].
Here we describe another example of potential regulation
of a remodelling ATPase by acetylation. We found that
Drosophila  ISWI, the founding member of a family of
nucleosome remodelling ATPases, was preferentially
acetylated by GCN5 at a single lysine within a amino acid
sequence of high similarity to the N-terminus of histone
H3. This acetylated lysine corresponds to lysine 14 in his-
tone H3 (H3K14), a known target for GCN5, suggesting
that this acetyltransferase may affect the chromatin struc-
ture by two distinct strategies: by acetylation of the nucle-
osomes and by modification of a nucleosome
remodelling enzyme.
Results
ISWI is acetylated in vivo
In order to explore whether ISWI was acetylated in Dro-
sophila cell lines we immunoprecipitated the ATPase from
extracts of SF4 cells (Figure 1A, lanes 1–3). Probing the
precipitate with a pan-acetyl-lysine antibody (αAcLysine)
we detected a labelled protein migrating at the position of
ISWI (Figure 1A, lanes 4, 5). To facilitate detection of
acetylated ISWI we treated Kc cells with the histone
deacetylase inhibitor Trichostatin A (TSA), prepared
whole cell extracts and monitored ISWI levels (Figure 1B,
lanes 1, 2). We then immunoprecipitated ISWI or proteins
containing acetylated lysines from these extracts. In the
absence of TSA ISWI was barely detectable in the αAcLy-
sine precipitate, which may be due to the inefficiency of
the antibody and/or the small amounts of acetylated ISWI
present in Kc cells (Figure 1B, lanes 3–5). However, upon
overnight TSA treatment the levels of acetylated ISWI
increased significantly (Figure 1B, lanes 6–8). Taken
together these results suggested that a minor fraction of
ISWI was acetylated in Kc and SF4 cells. In order to con-
firm this notion by an independent experiment we meta-
bolically labelled SF4 and Kc cells by addition of [3H]-
acetic acid for 3 hrs to the growth medium, prepared
extracts and determined the ISWI levels as before (Figure
1C, lanes 9, 10). ISWI was immunoprecipitated from
these extracts (Figure 1C, lanes 5–8) and acetylated pro-
teins in the precipitate were detected by gel electrophore-
sis and autoradiography. A band migrating at the position
of ISWI was only detectable in the αISWI precipitate, but
was absent in the control (Figure 1C, lanes 1–4). A second
labelled band points to an acetylated ISWI-associated pro-
tein of unknown identity (asterisk in Figure 1C). Collec-
tively, these data demonstrate that a relatively minor
fraction of ISWI is acetylated in Drosophila tissue culture
cells.
Histone acetyltransferases with substrate preference for 
the histone H3 N-terminus acetylate ISWI in vitro
We wished to identify acetyltransferases able to acetylate
ISWI. Towards this end we expressed and purified GCN5,
p300 and MOF and confirmed their activity and specifi-
city on histone substrates. In agreement with published
work [12-14], GCN5 only acetylated histone H3, p300
mainly acetylated H3 and to a lesser extent H4 and MOF
preferred histone H4 as a substrate (Figure 2A). Replacing
the histone substrate with recombinant ISWI we found
that GCN5 and p300 were also able to acetylate ISWI,
whereas MOF did not (Figure 2B). The activity of all HATs
in these assays is conveniently controlled by their
autoacetylation (bands labelled with asterisks in Figure
2B). Interestingly, the ability to acetylate ISWI correlated
with the enzymes' preference for H3 among the histones.
Because acetylation of ISWI by GCN5 was particularly
robust, we employed GCN5 in the subsequent analyses.
GCN5 acetylates ISWI at lysine 753
We next wished to identify the site(s) at which ISWI was
acetylated by GCN5 in vitro. The ATPase domain of ISWI
is located in the central part of the protein (Figure 3A).
While more N-terminal sequences of the protein have noBMC Molecular Biology 2007, 8:73 http://www.biomedcentral.com/1471-2199/8/73
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discernable features, the structure and function of the C-
terminal third are better known. A region defined by
HAND, SANT and SLIDE domains harbours a prominent
nucleosome recognition module [15]. At the very C-termi-
nus an ACF1-interaction determinant (AID) has been
described [16]. A panel of different ISWI fragments fused
to hexahistidine- (His6-) or GST-tags (Figure 3) were
expressed in E. coli and used as substrates for GCN5-
dependent acetylation. Acetylation of the first 697 N-ter-
minal amino acids (aa) of ISWI containing the ATPase
domain and sequences up to the HAND domain was
barely detectable (Figure 3B, lane 1). By contrast, the
remaining C-terminal part (aa 691–1027) was strongly
labelled (Figure 3B, lane 2). Trimming this fragment from
the C-terminus to aa 962 did not affect its acetylation,
however, deleting amino acids between 691 and 796
abolished the acetylation (Figure 3B, lanes 4–7). We con-
cluded that a prominent acceptor site for acetylation must
reside within the HAND fold [15]. This region of ISWI
contains 10 lysines that could potentially be acetylated.
Upon closer inspection we found the region between aa
747 and 756 to be remarkably similar to the N-terminus
of histone H3 (Figure 4A). In this alignment ISWI residues
748 and 753 (K748 and K753, respectively) correspond to
lysines 9 and 14 of H3, which are frequently acetylated by
GCN5. These ISWI residues and their sequence context are
conserved in Xenopus laevis (xISWI) and the human ISWI
ISWI is acetylated in vivo Figure 1
ISWI is acetylated in vivo. (A) ISWI was immunoprecipitated from whole cell extracts of Drosophila SF4 cells. A parallel 
immunoprecipitation (IP) with rabbit IgG antibodies served as specificity control. Enrichment of ISWI was documented by 
Western blotting (WB) using an αISWI antibody (lanes 1–3). A pan-acetyl-lysine (αAcLysine) antibody detects a protein co-
migrating with ISWI (lanes 4, 5). (B) Kc cells were cultured for 17 hrs in the presence or absence (control) of 200 ng/ml tri-
chostatin A (TSA). Whole cell extracts contained equal amounts of ISWI (lanes 1, 2). Proteins were immunoprecipitated from 
these extracts with αISWI or αAcLysine antibody as indicated. ISWI was detected in the precipitate by Western blot analysis. 
(C) Drosophila SF4 and Kc cells were metabolically labelled with [3H]-acetic acid and extracts prepared. Extract ISWI levels 
were visualised by Western blotting (lanes 9, 10). ISWI was immunoprecipitated from these extracts and visualised by Western 
blotting (lanes 5–8). An equivalent gel was then autoradiographed (lanes 1–4) in order to detect acetylated protein. The arrow 
points to the position of ISWI, the asterisk indicates an unknown acetylated protein.BMC Molecular Biology 2007, 8:73 http://www.biomedcentral.com/1471-2199/8/73
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isoforms hSNF2H and hSNF2L (Figure 4A). We therefore
focused our attention on this part of ISWI.
A peptide corresponding to aa 1–19 of histone H3 is
acetylated rather well by GCN5 and p300 in a standard
HAT reaction, but less by MOF (Figure 4B, left panel). By
direct comparison, a peptide spanning the corresponding
19 aa of ISWI (Figure 4A) is well acetylated by GCN5, but
not at all by MOF (Figure 4B, right panel). Maldi-TOF
mass spectrometry and nano-electrospray sequencing
documented that the peptide was mono-acetylated (Fig-
ure 4C) exclusively at K753 (Figure 4D). In order to test
for the contribution of K753 to ISWI acetylation in the
context of the entire protein we expressed recombinant
ISWI derivatives that had either K748 or K753 or both
lysines replaced by alanines (A) or arginines (R). Equiva-
lent protein amounts (Figure 4E, lower panel) were used
as substrate for GCN5-dependent acetylation reactions.
The ISWI derivative bearing the K748A mutation was
acetylated as the wildtype protein, whereas replacement of
lysine 753 by alanine (K753A) led to a significantly
reduced acetylation (Figure 4E, compare lanes 4, 5). Col-
lectively the data identify K753 of ISWI, which appears
related by sequence context to H3K14, as the major target
of acetylation by GCN5 in vitro.
We were not able to evaluate the effect of acetylation on
ISWI ATPase activity due to the small fraction of ISWI
modified in these in vitro reactions. However, replacement
of either lysine 753 or lysine 748 (which corresponds to
lysine 9 in H3) by arginine or alanine did not affect the
ATPase activity in response to DNA or nucleosomes (Fig-
ure 4F).
ISWI is acetylated at K753 by GCN5 in vivo
In order to monitor the distribution of ISWIK753ac in vivo
we raised an antibody against an ISWI peptide acetylated
at K753. The antibody recognised ISWI only after acetyla-
tion by GCN5 (Figure 5A, lanes 5, 6) and did not cross-
react with H3 even when the histone was acetylated to
much higher levels (Figure 5A, B; compare lanes 4 and 6).
The antibody precipitated ISWI from Drosophila embryo
extracts (Figure 5C) as well as a protein of the size of ISWI
that was stainable with the ISWIK753ac antibody (Figure
5D).
The antibody also recognised an epitope in nuclei of Dro-
sophila SL2 cells (Figure 6B, upper left panel). To confirm
that the antibody reactivity was specific in vivo we per-
formed RNA interference on SL2 cells with dsRNA corre-
sponding to ISWI or GCN5 sequences and monitored the
success of the knockdown by Western blotting of whole
cells extracts (Figure 6A) and immunofluorescence (Fig-
ure 6B). Knocking down either ISWI or GCN5 slowed cell
proliferation effectively increasing the doubling time two
fold. Ablation of ISWI removed not only the signal
obtained with the ISWI antibody, but also the ISWIK753ac-
specific signal (Figure 6B). Remarkably, knockdown of
GCN5 also greatly reduced the signal obtained with the
ISWIK753ac antibody, but did not affect ISWI in general
(Figure 6B). Taken together, these data document the spe-
cificity of the antibody for ISWIK753ac in immunofluores-
cence applications. They also show that ISWI is acetylated
at K753 by GCN5 in SL2 cells.
Acetylated ISWI may reside in the NURF complex, but not 
in CHRAC/ACF
So far ISWI is known to reside in two kinds of nucleosome
remodelling complexes in Drosophila: CHRAC/ACF,
which are characterised by the ACF1 subunit, and NURF,
which contains NURF301 as a defining feature [17]. In
order to explore whether ISWIK753ac  was preferentially
associated with one of these complexes we ablated the sig-
nature subunits ACF1 and NURF301 by RNA interference
in SL2 cells (Figure 6A) and found that the ISWIK753ac
epitope was significantly reduced in the absence of
NURF301, but remained unperturbed if ACF1 was
knocked down (Figure 6B). In agreement with the notion
that ISWIK753ac is not a subunit of CHRAC/ACF we found
that the expression pattern of the acetylated ISWI form
was unperturbed in acf1  null flies (data not shown).
In vitro, ISWI is specifically acetylated by HATs able to modify  histone H3 Figure 2
In vitro, ISWI is specifically acetylated by HATs able 
to modify histone H3. (A) The histone acetyltransferase 
activities of recombinant GCN5, p300 and MOF were 
assayed in reactions containing all four histones. Incorpora-
tion of [3H]-acetyl-coenzyme A leads to labelled proteins, 
which are separated by SDS-PAGE and detected by autoradi-
ography of the gel. Bands corresponding to acetylated his-
tones are marked by arrows. (B) Recombinant ISWI was 
incubated in acetylation reactions with GCN5, p300 or MOF. 
Acetylated ISWI (arrow) was detected as in (A). All other 
bands (asterisks) are due to auto-acetylation of the corre-
sponding enzyme.BMC Molecular Biology 2007, 8:73 http://www.biomedcentral.com/1471-2199/8/73
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ISWIK753ac staining was unperturbed in flies heterozygous
for the NURF301 allele [E(bx)ry122] [18]. Homozygous
mutants are lethal, but survive until the end of the larval
stage due to maternal contribution of NURF301 and were
not analysed. Immunoprecipitation of NURF301 from
extracts of SL2 cells and 8–12 hr embryos co-precipitated
acetylated ISWI, which was not the case if ACF1 was pre-
cipitated (Figure 6C, D). We conclude that in SL2 cells
ISWI may be acetylated in the context of NURF but is not
acetylated in association with ACF1. The data do not
exclude the existence of additional complexes harbouring
the modification.
Discussion
Many acetyltransferases were first identified following
their histone acetylation function and hence named his-
tone acetyltransferases (HATs). However, most of them
have now been shown to acetylate non-histone proteins
as well, and these modifications can have profound effects
on the structure and function [19]. For example, the
effects of acetylation on the tumour suppressor protein
p53 have been heavily studied [20]. The current work,
together with the earlier observation that the effect of the
BRM ATPase on cell proliferation can be regulated by
acetylation [10] highlight the potential for direct regula-
tory cross-talk between different chromatin modifying
principles [21].
The fact that ISWI can be acetylated in vitro and in tissue
culture cells by GCN5, which is also known to target the
H3 N-terminus, is explained by the sequence similarity
between the histone and ISWI around the K753 acetyla-
tion site. The common motif RKT/SxGx(Kac)xPR/K differs
from the previously suggested GCN5/PCAF recognition
motif GKxxP [19]. This raises the possibility of specific co-
regulation of a nucleosome remodelling factor and its
nucleosome substrate through acetylation of related
epitopes. Strikingly, the related motif DKGKGKKRP also
occurs in the C-terminus of hBRM, overlapping with
potential acetylation sites [10]. Acetylation at one or more
C-terminal lysines of BRM correlates with reduced inter-
ference with cell cycle progression in mammalian cells
and mutation of several of these lysines into arginines
impairs BRM function. The data suggest that site-specific
acetylation of the ATPase by, for example P/CAF, may
adversely affect its function, possibly by interfering with
targeting interactions [10].
The fact that the acetylated ISWI epitope is conserved dur-
ing evolution suggests functional significance. However,
so far we were unable to document an effect of acetylation
on the catalytic properties or protein interactions of ISWI,
due to the small proportion of ISWI either acetylated in
vitro or naturally present in vivo. Lysine 753 of ISWI resides
in the HAND domain, a fold of unknown function situ-
ated between the ATPase domain and the C-terminal
SANT/SLIDE domains that mediate nucleosome interac-
tions [15]. Exploring the role of the HAND domain in
ISWI may lead to novel approaches towards evaluating
the impact of K753 acetylation. Applying the K753ac-spe-
cific antibody to developmental stages of Drosophila
revealed that the acetylation of ISWI is a developmentally
regulated process, which occurs during oogenesis and
early embryogenesis, but is absent from later develop-
mental stages (CC and PBB, unpublished observations).
We also obtained preliminary support for the idea that the
acetylation of ISWI marks a functionally distinct subpop-
ulation: the acetylated epitope was dramatically enriched
ISWI is acetylated in the HAND domain Figure 3
ISWI is acetylated in the HAND domain. (A) Schematic 
representation of ISWI, the extent of known domains (first 
line) and of deletion mutants used for mapping the acetyla-
tion site. Numbers correspond to the first and the last amino 
acids of the proteins. They were expressed in E. coli with 
either HIS6- or glutathione-S-transferase- (GST-) tags. (B) 
The different ISWI fragments displayed in (A) were 
acetylated in vitro with GCN5. Reactions were resolved by 
SDS-PAGE and visualized by autoradiography (upper panel) 
and Coomassie staining (lower panel). Black dots label the 
positions of the ISWI fragments. An asterisk marks the band 
corresponding to GCN5.BMC Molecular Biology 2007, 8:73 http://www.biomedcentral.com/1471-2199/8/73
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GCN5 acetylates ISWI at K753 Figure 4
GCN5 acetylates ISWI at K753. (A) Alignment of Drosophila ISWI sequences spanning aa 740–769 with the corresponding 
residues from Xenopus ISWI (xISWI), human hSNF2H, hSNF2L and with the 30 N-terminal amino acids of histone H3. A con-
sensus of highly conserved residues is given. The arrowhead points to K753 indISWI. (B) Peptides corresponding to the his-
tone H3 N-terminal tail (aa 1–19, left panel) and to aa 740–759 of ISWI (right panel) were acetylated in vitro by GCN5, p300 or 
MOF as in Figure 2. Peptide acetylation was determined from incorporation of [3H]-acetate and by subtracting the values for 
autoacetylation of enzymes (from reactions lacking substrate) and the values for non-specific adsorption of label to the pep-
tides (from reactions lacking enzyme) from the experimental values. (C) MALDI analysis of the in vitro acetylated ISWI peptide 
(aa 740–759). The acetylation reaction was stopped by addition of 10% acetic acid, and the reaction products were analyzed by 
MALDI-TOF. The upper spectrum represents the unmodified peptide (M-H+ = 2580.29 amu) from a control reaction lacking 
acetyl-CoA. In the lower spectrum the arrow points to a peak representing the product of the acetylation reaction (M-H+ = 
2622.32 amu). A Deltamass (Dm) of 42.01 amu indicates mono-acetylation. A second peak of very low intensity (asterisk) sug-
gests minor di-acetylation (M-H+ = 2664.33). (D) Nanospray sequencing of ISWI peptide (aa 743–759) after in vitro acetylation 
and removal of the C-terminal cysteine by V8 protease. Upper spectrum: sequencing of the unmodified peptide with a (M-3H+) 
value of 702.67 confirms the sequence IYYFRKTVGYKVPKNTE with unmodified K748, K753 and K756. The spectrum is 
enlarged over the region 750VGYKV754 in order to observe the y7 ion (M-H+ = 815.46) corresponding to the unacetylated 
K753. Lower spectrum: sequencing of the peptide with a (M-3H+) value of 716.73 reveals the sequence IYYFRKTVGYKAcVP-
KNTE, with only K753 being acetylated, (mass of the y7 ion M-H+ = 857.47, which differs in mass from the corresponding 
unmodified y7 ion in the upper spectrum by 42.012 amu). Detailed analysis of K748 and K756 revealed no acetylation at these 
sites (data notshown). (E) Recombinant ISWI and derivatives bearing the indicated point mutations were acetylated by GCN5 
and acetylated proteins were visualized by autoradiography (upper panel) and Coomassie staining (lower panel). (F) Recom-
binant wildtype (WT) and mutant ISWI proteins were incubated with [g-32P]-ATP in the absence (control), or presence of 110 
ng of free or nucleosomal DNA (Nuc) as indicated. ATP hydrolysis was detected by thin-layer chromatography and quantified 
by PhosphoImager analysis. ATPase activity is indicated as percentage of ATP hydrolysed.BMC Molecular Biology 2007, 8:73 http://www.biomedcentral.com/1471-2199/8/73
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on the condensed metaphase chromosomes in early
embryos (CC and PBB, unpublished observations). A
causal role between the acetylation and the unusual abil-
ity of the ATPase to interact with compact chromatin
remains to be explored.
The ATPase ISWI is the catalytic moiety of several nucleo-
some remodelling complexes. Better known and charac-
terized are the factors CHRAC, ACF and NURF (for review,
see [22]. The available data suggest that the acetylated
form of ISWI may mark a subpopulation of the NURF
complex. NURF is involved in the transcription of selected
sets of Drosophila genes [18,23] but flies mutant for the
large, defining NURF301 subunit also show defects of
chromosome structure [23]. Assessment of which of these
functions may be modulated by ISWI acetylation requires
a genetic approach.
The acetylation of the amino terminus of histone H3 is an
important determinant of active chromatin, but chroma-
tin structure can also be modulated by other modifica-
tions of the histone 'tail', notable its methylation or
phosphorylation. Whether the analogy between the ISWI
and the H3 N-terminus can also be extended to include
phosphorylation and methylation remains an interesting
aspect for future research.
Characterisation of an antibody specific forISWIK753ac Figure 5
Characterisation of an antibody specific forISWIK753ac. (A) Recombinant ISWI was acetylated by GCN5 in the presence 
of radiolabeled acetyl-CoA. The protein mixture was separated by SDS-PAGE and visualized by Coomassie staining (left panel), 
by autoradiography (centre panel) and by Western blotting using an antibody raised against an ISWI peptide bearing acetylated 
K753 (αISWIK753ac). The asterisk points to the position of GCN5 in the gel (lane 2), which autoacetylates itself (lane 4). (B) The 
antibody does not cross-react with acetylated H3. Recombinant histone H3 was acetylated with GCN5 in presence of radiola-
beled acetyl-CoA and analysed as in (A). Western blotting on such a substrate using αISWIK753ac did not reveal any cross-reac-
tivity. (C) ISWI was immunoprecipitated from embryonic nuclear extract using antibodies against ISWI or ISWIK753ac and 
detected by Western blotting. (D) αISWIK753ac immunoprecipitates were analysed by Western blotting for the presence of 
acetylated ISWI.BMC Molecular Biology 2007, 8:73 http://www.biomedcentral.com/1471-2199/8/73
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Conclusion
We identified and characterised a site-specific acetylation
of the remodelling ATPase ISWI by GCN5. The modifica-
tion occurs predominantly in the context of the remodel-
ling factor NURF, however, due to the fact that the
acetylation marks a minor subpopulation of the remodel-
ler a functional evaluation of the modification has not yet
been achieved.
Methods
Recombinant DNA technology
pGEX-4T-3 and pProEx-Htb vectors for expression of GST-
ISWI and (His6)-ISWI deletion mutants, respectively have
been described earlier [15,16]. pFastBacHTa-FLAG-ISWI
WT was generated by inserting the NcoI-KpnI fragment
from pMYB4-FLAG-ISWI WT [24] into pFastBacHTa vec-
tor ("Bac-to-Bac" expression system, Invitrogen). pMYB4-
FLAG-ISWIK748A, -ISWIK753A, -ISWIKK748/753AA and
-ISWIKK748/753RR were generated using the Quick-
Change site-directed mutagenesis kit (Stratagene) with
primers listed in the supplemental materials and moved
as NcoI-KpnI fragments into the pFastBacHTa vector.
Primers used for site-directed mutagenesis
Generation of ISWIK748A:
CCAGGAAATCTACTATTTCCGGGCCACTGTTGGTTAC
and
GTAACCAACAGTGGCCCGGAAATAGTAGATTTCCTGG.
Generation of ISWIK753A:
GTTGGTTACGCGGTACCCAAGAACACGGAACTAGG
and
CCTAGTTCCGTGTTCTTGGGTACCGCGTAACCAAC.
Generation of ISWIK748R:
CCAGGAAATCTACTATTTCCGGAGGACCGTTGGTTAC
and
GTAACCAACGGTCCTCCGGAAATAGTAGATTTCCTGG.
Generation of ISWIK753R
GTTGGTTACCGAGTGCCCAAGAACACGGAACTAGG
and
CCTAGTTCCGTGTTCTTGGGCACTCGGTAACCAAC
Primers used for PCR to generate dsRNA fragments for 
RNA interference
ISWI sequences 1–499:
Acetylated ISWI may reside in the NURF complex, but not in  CHRAC/ACF in SL2 cells Figure 6
Acetylated ISWI may reside in the NURF complex, 
but not in CHRAC/ACF in SL2 cells. (A) Ablation of 
proteins by RNA interference. Drosophila SL2 cells were 
treated with double-stranded RNA (RNAi) to interfere with 
the expression of ISWI, ACF1, NURF301, GCN5 or GST (to 
control for non-specific effects of dsRNA treatment). After 
10 days of incubation whole cell lysates were prepared and 
probed by Western blotting (WB) for the presence of 
NURF301, ACF1, ISWI, GCN5 and p55 (a subunit of NURF 
that serves as a loading control). (B) SL2 cells were treated 
for 12 days with dsRNAs as indicated. Localization of 
ISWIK753ac or bulk ISWI was monitored by immunofluores-
cence staining using the indicated antibodies. DNA was coun-
terstained with Hoechst 33258. (C) SL2 whole cell extract 
(upper panel) or nuclear extract from 8–12 hr embryos 
(lower panel) were subjected to immunoprecipitation with 
antibodies against ISWI, ACF1 or NURF301. The presence of 
bulk ISWI (left panel) or ISWIK753ac (right panel) in the immu-
noprecipitates was analysed by Western blotting.BMC Molecular Biology 2007, 8:73 http://www.biomedcentral.com/1471-2199/8/73
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TTAATACGACTCACTATAGGGAGAATGTCCAAAACAGA-
TACAGCTG and
TTAATACGACTCACTATAGGGAGAGCAGAGATAT-
GGTCTGCAGG;
GCN5 sequences 1–525:
TTAATACGACTCACTATAGGGAGAATGTCTGGTGGTC-
CATCC and
TTAATACGACTCACTATAGGGAGAGCGCTGCATGGA-
CATGAA;
ACF1 sequences 1–560
TTAATACGACTCACTATAGGGAGAATGCCCATTT-
GCAAGCGG and
TTAATACGACTCACTATAGGGAGAAT-
GCGCGAGCGACGTAAT;
NURF301 sequences 1–521
TTAATACGACTCACTATAGGGAGAATGAGCGGTCGCG-
GCAG and
TTAATACGACTCACTATAGGGAGAGCTGCATACTGAC-
GACCT;
GST sequences 1–527;
TTAATACGACTCACTATAGGGAGAATGTC-
CCCTATACTAGGTTA and
TTAATACGACTCACTATAGGGAGAACGCATCCAGGCA-
CATTG;
Antibodies
The following antibodies were kind gifts: αISWI (J. Tam-
kun, UC St. Cruz), αp55 (C. Wu, NIH, Bethesda), αGCN5
(Jerry Workman, Stowers Institute for Medical Research)
αNURF301 (Andreas Hochheimer). The monoclonal
αACF1 antibody was raised in rats. Its specificity was con-
firmed using the acf1 null fly strain [25] (C. Chioda et al,
manuscript in preparation). We employed two different
pan-acetyl-lysine antibodies for immunoprecipitation
[26] and Western blotting (Cell Signalling Technology #
9441). The αISWIK753ac was raised against ISWI peptide
TVGYKacVPKNT (aa 749–758) where K753 was
acetylated. The antibody is available from Abcam
(ab10748). As control antibody we used rabbit IgG (sc-
2027, Santa Cruz Biotechnology). The αH3S10p antibody
was from Upstate (RR002, catalog # 05–598).
Cell culture, RNA interference and immunostaining
Drosophila SF4 cells (an SL2 clone sorted for diploidy and
adherence) were provided by D. Arndt-Jovin (Göttingen).
SF4, Kc and SL2 cells were maintained at 26°C in Schnei-
der's Drosophila medium (Invitrogen) supplemented
with 10% fetal calf serum (FCS), antibiotics and
glutamine. When needed, trichostatine A (TSA) was
added at a final concentration of 200 ng/ml to the
medium for 17 hrs before harvesting the cells. RNAi
experiments were performed as described [27]. The prim-
ers used to generate the double-stranded RNA are listed in
the supplemental materials. Briefly, 1–2 × 106 SL2 cells
were seeded into 6-wells plates in 1 ml of medium with-
out FCS just before adding 10 µg of dsRNA. Plates were
then placed onto a shaking platform for 10 min and then
for 50 min at 26°C. 2 ml of medium complemented with
FCS were then added to the cells and incubated at 26°C.
Cells were collected 10 or 12 days after dsRNA treatment.
Protein extractions for Western blot analysis after RNAi,
1–2 × 106 cells were pelleted and lysed in 50 µl of urea
buffer (8 M urea, 5% SDS, 200 mM Tris-Cl pH 6.8, 0.1
mM EDTA, 100 mM DTT) and incubated at 65°C for 15
min. Immunostainings were performed as described [28].
For immunostaining following RNAi, cells were collected
12 days after dsRNA treatment. After fixation, permeabili-
sation and blocking, cells were incubated for 1 hr with
antibody against ISWI, diluted 1:600 in blocking solution
(2% BSA and 5% goat serum in PBS), or aISWIK753ac,
diluted 1:300. After washes, cells were incubated for 1 hr
with Cy3-conjugated secondary antibody (Jackson Immu-
noresearch Laboratories) diluted in blocking buffer. Cells
were washed four times in PBS. DNA was counterstained
with 1 µg/ml bisbenzimide (Hoechst 33258). Slides were
mounted using 1.5% n-propyl gallate, 50% glycerol in
PBS. Images were acquired using a Zeiss Axiophot micro-
scope coupled to a Retiga Exi CCD Camera (Qimaging,
Burnaby, Canada). Images were cropped and levels
adjusted in Photoshop.
Immunoprecipitation
Total cell extracts were prepared as described [29] from 4
× 107 Drosophila cells. All steps were performed at 4°C.
Cells were washed with PBS, resuspended in 1 volume of
lysis buffer (50 mM Tris-Cl pH 8.0, 300 mM NaCl, 10 mM
MgCl2, 0.4% NP40 and proteases inhibitors) and incu-
bated for 15 min. The supernatant was cleared by centrif-
ugation and mixed with 1 volume of dilution buffer (50
mM Tris-Cl pH 8.0, 0.4% NP40). Diluted extracts were
pre-cleared with protein A/protein G Sepharose beads
(Amersham Biosciences) and incubated with αISWI,
αAcLysine or irrelevant antibodies, and immunoprecipi-
tated with protein A/protein G Sepharose beads. Follow-
ing extensive washing with a 1:1 mix of lysis and dilution
buffer, beads were resuspended in Laemmli buffer and
proteins were analyzed by Western blot analysis.BMC Molecular Biology 2007, 8:73 http://www.biomedcentral.com/1471-2199/8/73
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Western Blot Analysis
Immunoprecipitated proteins were separated by SDS-
PAGE, electro-transferred onto PVDF or nitrocellulose
membranes and detected using an ECL kit (Amersham
Biosciences) according to the manufacturer's instructions.
In vivo labeling
Drosophila cells were treated with 0.5 mCi/ml [3H]-acetic
acid (TRK12, Amersham Biosciences) and 10 mM sodium
butyrate (NaB) for 3 hrs at 26°C. Whole cell extracts and
immunoprecipitations were performed using standard
procedures, except that all buffers were complemented
with 5 mM sodium butyrate. Immunoprecipitated pro-
teins were analyzed by Western blot or by autoradiogra-
phy.
Recombinant proteins
FLAG-ISWI mutants were expressed and purified from
baculovirus vectors in Sf9 cells as described [30]. Expres-
sion of proteins in E. coli and purification was according
to the following published procedures: FLAG-ISWI and
HIS6-ISWI deletion mutants [15]; GST-ISWI deletion
mutants [16]; GST-hGCN5 and FLAG-p300 [31]; MOF
[13].
In vitro acetylation assays
200 ng of FLAG-ISWI, 200 ng of His- or GST-ISWI deletion
mutants, 2 µg of histone octamers or 200 ng of bacterially
expressed histone H3 were incubated for 30 min at 26°C,
in 20 µl final volume with 0.25 mCi of [3H]-acetyl-CoA
(4.1 Ci/mmol, TRK688, Amersham Biosciences), 50 to
100 ng of GST-hGCN5, HA-MOF or FLAG-p300 in HAT
buffer (10 mM Tris-Cl pH 7.8, 0.1 mM EDTA, comple-
mented with 1 mM PMSF, 1 mM DTT and 10 mM NaB).
Reaction mixtures were analyzed by SDS-PAGE. The gel
was Coomassie stained, destained, treated with Amplify
(Amersham Biosciences) for 30 min, dried and autoradi-
ographed. 1 µg each of an H3 peptide (aa 1–19) or an
ISWI peptide (aa 740–759) were acetylated under the
same conditions. A 10 µl aliquot of each reaction was
spotted onto p81 filters (Whatman), which were washed
three times with 50 mM NaCarbonate pH 9.2 and
counted in a scintillation counter.
Sequence alignment
Sequence alignment was performed using ClustalW soft-
ware, using default parameters.
Mass spectrometry
MALDI-TOF analysis of acetylated ISWI peptide. The in vitro
acetylated peptides were purified on C18 reversed phase
ZipTip mini-columns (Millipore) according to the manu-
facturer's protocol. In short the peptide was washed 3
times with 0.1% TFA, eluted with 1 µl of matrix solution
[saturated a-cyanohydroxy-cinammic acid (Sigma) dis-
solved in 50% ACN (v/v)/0.3% TFA (v/v)] directly onto
the target plate. The peptide-matrix co-crystal was ana-
lyzed in a Voyager DE STR spectrometer according to the
manufacturer's instructions. Peptide mass fingerprints
covered the mass range between 700–3500 amu, with the
low mass gate set at 500 amu. The accelerating voltage was
set to 20 kV, the grid to 66% and the delay time to 100
nsec.  ESI-analysis. The ISWI peptide DQEIYYFRKTV-
GYKVPKNTEC plus a C-terminal cysteine (aa 740–759,
M-H+ = 2580,27 amu) was digested with V8 protease. The
resulting peptide IYYFRKTVGYKVPKNTE (M-H+  =
2106.14 amu) was de-salted, concentrated using a C18
reversed phase minicolumn (Eppendorf) and eluted in
0.5 µl 50% Methanol, 0.1% FA into medium size nano-
spray needles (Protana, Odense, Denmark). ESI mass
spectra were recorded on an Applied Biosystems QStar XL
hybrid quadrupole time of flight mass spectrometer,
equipped with a Protana nano-spray ion source in the
static nano-spray mode according to the manufacturer's
instructions. The needles were adjusted in front of the ori-
fice and the spray voltage was set between 950 and 1100
V. Product ion scans were acquired for 4–5 min contain-
ing approximately 200–300 scans.
ATPase assays
The ATPase assays were performed as described previously
[30].
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